Suppr超能文献

先天性肝外门体分流症肝移植的长期预后。

Longterm Outcome of Liver Transplantation for Congenital Extrahepatic Portosystemic Shunt.

机构信息

Organ Transplantation Center National Center for Child Health and Development Tokyo Japan Department of Pediatric Surgery Tohoku University Miyagi Japan Department of Pediatric Surgery Kanazawa Medical University Ishikawa Japan Department of Surgery Osaka University Osaka Japan Department of Gastroenterological and Transplant SurgeryApplied Life SciencesInstitute of Biomedical and Health Sciences Hiroshima University Hiroshima Japan Department of SurgeryInstitute of Gastroenterology Tokyo Women's Medical University Tokyo Japan Department of Surgery Kyoto University Kyoto Japan.

出版信息

Liver Transpl. 2021 Feb;27(2):236-247. doi: 10.1002/lt.25805. Epub 2020 Aug 6.

Abstract

Liver transplantation (LT) is often viewed as the last resort for the treatment of congenital extrahepatic portosystemic shunt (CEPS) due to advancement of imaging and interventional radiology techniques. However, some patients still require LT, and criteria for LT are yet to be determined. We conducted a national survey of patients undergoing LT for CEPS between June 1998 and August 2018 and evaluated the clinical data and outcomes with a review of previously reported patients from the English-language medical literature. A total of 26 patients underwent LT in Japan at a median age of 5.2 years old. The most common indications for LT were persistent hyperammonemia (54%) and liver mass (50%), followed by pulmonary complications (38%). Pulmonary complications in all patients, including intrapulmonary shunt and pulmonary hypertension (PH), were improved after LT. Regarding the 29 previously reported patients in the English-language literature, a liver nodule (49%), including hepatoblastoma and hepatocellular carcinoma, was the most common indication for LT, followed by pulmonary complications (34%). A total of 25 (96%) patients in our survey and 26 (90%) patients in the literature review were alive with a median follow-up period of 9.5 and 1.6 years, respectively. Although LT has a limited role in management of CEPS, our study indicated that LT was safe as an alternative treatment for select patients with malignant tumor or pulmonary complications and those with complications related to new portosystemic collateral vessels after shunt closure, such as PH or hepatopulmonary syndrome.

摘要

肝移植(LT)通常被视为先天性肝外门体分流(CEPS)治疗的最后手段,因为影像学和介入放射学技术的进步。然而,一些患者仍需要 LT,并且 LT 的标准尚未确定。我们对 1998 年 6 月至 2018 年 8 月期间接受 LT 治疗的 CEPS 患者进行了一项全国性调查,并通过回顾英语医学文献中先前报道的患者评估了临床数据和结果。共有 26 名患者在日本接受 LT,中位年龄为 5.2 岁。LT 的最常见适应证是持续性高氨血症(54%)和肝肿大(50%),其次是肺部并发症(38%)。所有患者的肺部并发症,包括肺内分流和肺动脉高压(PH),在 LT 后均得到改善。关于英语文献中先前报道的 29 例患者,肝结节(49%),包括肝母细胞瘤和肝细胞癌,是 LT 的最常见适应证,其次是肺部并发症(34%)。在我们的调查中,共有 25 名(96%)患者和文献综述中 26 名(90%)患者存活,中位随访时间分别为 9.5 年和 1.6 年。尽管 LT 在 CEPS 管理中的作用有限,但我们的研究表明,LT 作为恶性肿瘤或肺部并发症患者以及分流关闭后与新门体侧支血管相关并发症(如 PH 或肝肺综合征)的患者的替代治疗是安全的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验